Brookhaven Instruments’ NanoBrook 90Plus Particle Size Analyzer and NanoBrook ZetaPALS, were used in a study entitled, “Polymeric Nanoparticles for Drug Delivery”. The study highlighted the significance of using biodegradable polymeric nanoparticles (NPs) for controlled drug delivery.
Juliana Chan and her team of researchers used Brookhaven’s NanoBrook 90Plus Particle Size Analyzer and NanoBrook ZetaPALS to characterize the polymers and nanoparticles used for the purpose of this study. The polymers and nanoparticles were subjected to tests that aimed to describe the preparation and characterization of prostate cancer-targeted, biodegradable and biocompatible NPs as a model controlled-release drug delivery platform. The researchers used functionalized NPs using the A10 2’-fluoropyrimidine ribonucleic acid (RNA) aptamers as model targeting moiety, which binds to the prostrate-specific membrane antigen (PSMA). The study was able to demonstrate methods contributed to the development of other useful polymeric NPs to deliver an array of chemotherapeutic, diagnostic and imaging agents for various applications.
For the treatment of cancer, targeted polymeric NPs are used to deliver chemotherapy to tumor cells more effectively and lessen cytotoxicity on peripheral healthy tissues. Targeted delivery technologies and biodegradable polymeric NPs for targeted drug delivery are important scientific areas of investigation in present day medical advances. Accurate and reliable results are they key to ensuring successful research. Brookhaven Instruments features equipment that is accurate, technologically competitive and convenient to use. The NanoBrook 90Plus Particle Size Analyzer and NanoBrook ZetaPALS are among Brookhaven Instruments’ prestigious equipment that meets all the requirements for effective particle characterization.